세계의 당뇨병 망막증 시장 : 시장 규모, 점유율, 동향 분석(유형별, 관리법별, 지역별), 부문별 예측(2025-2030년)

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative Diabetic Retinopathy), By Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,575,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,017,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,899,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

당뇨병 망막증 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 당뇨병 망막증 시장은 2030년까지 137억 7,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 CAGR 6.4%로 성장할 것으로 예측됩니다.

여러 지역에서 당뇨병 이환율 증가와 당뇨병 망막증(DR)의 효율적인 관리와 효과적인 치료의 중요성에 대한 의식 증가가 주요 시장 성장 촉진요인입니다. 제때 치료하지 않으면, DR은 심각한 시력 장애나 심지어 실명을 초래할 수 있습니다.

여러 지역에서 당뇨병으로 진단되는 환자 수가 대폭 증가하고 있는 것도 이 시장의 성장에 기여하고 있습니다.

미국 당뇨병 협회의 보고에 따르면 당뇨병 환자는 녹내장, 백내장, 황반부종 등의 안질환이 발병할 위험이 있습니다.

당뇨병 망막증 시장 : 분석 개요

• 비증식 당뇨병 망막증이 2024년에 70.0% 이상의 점유율을 차지하고 시장을 독점했습니다.
• 예측 기간 중 레이저 수술이 가장 빠른 CAGR을 나타낼 전망입니다.
• 안티 VEGF 관리 분야는 2024년92.3%의 최대 시장 점유율을 차지했습니다.
• 의료 투자 증가와 기술의 진보가 시장 성장에 기여했습니다.
• 북미는 인지도 향상, 정교한 의료 인프라, 안티 VEGF 약물의 높은 시장 침투로 세계 시장을 독점했습니다.
• 2024년 9월, 인도의 국가 규제 당국은 소개 가능한 DR의 자동 검출을 용이하게 하는 안과 AI 소프트웨어 Remidio Medios DR AI를 승인했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 당뇨병 망막증 시장 : 변동 요인 및 경향 및 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련, 부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 당뇨병 망막증 시장 : 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 당뇨병 망막증 시장 : 유형별 추정 및 동향 분석

• 유형별 대시보드
• 당뇨병 망막증 시장 : 유형별 변동 분석
• 세계의 당뇨병 망막증 시장 : 시장 규모의 예측과 동향 분석, 유형별(2018-2030년)
• 증식성 당뇨병 망막증
• 비증식성 당뇨병 망막증

제5장 당뇨병 망막증 시장 : 관리법별 추정 및 동향 분석

• 관리법별 대시보드
• 당뇨병 망막증 시장 : 관리법별 변동 분석
• 세계의 당뇨병 망막증 시장 : 시장 규모의 예측과 동향 분석, 관리법별(2018-2030년)
• 안티 VEGF
• 안내 스테로이드 주사
• 레이저 수술
• 유리체 절제술

제6장 당뇨병 망막증 시장 :지역별 추정 및 동향 분석

• 시장 대시보드 : 지역별
• 시장 점유율 분석 : 지역별(2024년 및 2030년)
• 연속 바이오프로세스 시장 : 주요 포인트, 지역별
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 태국
  • 호주
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업, 경쟁의 분류
• 벤더 상황
  • 주요 기업의 히트맵 분석(2024년)
• 기업 프로파일
  • Bayer AG
  • AbbVie Inc.
  • Novartis AG
  • Oxurion NV.
  • Sirnaomics, Inc.
  • Alimera Sciences
  • Ampio Pharmaceuticals Inc.
  • BCN Peptides
  • Kowa Company, Ltd.
  • Genentech, Inc.

SHW

영문 목차

영문목차

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market is anticipated to reach USD 13.77 billion by 2030 and expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

Diabetic Retinopathy Market Report Highlights:

• Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.
• Laser surgery is expected to grow at the fastest CAGR over the forecast period.
• The anti-VEGF management segment held the largest market share of 92.3% in 2024.
• The rise in healthcare investments and advancements in technology contribute to market growth.
• North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.
• In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Management
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. Management Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Diabetic Retinopathy Market Analysis tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Diabetic Retinopathy Market: Type Movement Analysis
• 4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Proliferative Diabetic Retinopathy
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Non-Proliferative Diabetic Retinopathy
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

• 5.1. Management Segment Dashboard
• 5.2. Diabetic Retinopathy Market: Management Movement Analysis
• 5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
• 5.4. Anti-VEGF
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Intraocular Steroid Injection
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Laser Surgery
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Vitrectomy
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Continuous Bioprocessing Market By Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.1.3. Competitive Scenario
    • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Thailand
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.1.3. Competitive Scenario
    • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key Country Dynamics
    • 6.8.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.1.3. Competitive Scenario
    • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.3.3. Competitive Scenario
    • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.4.3. Competitive Scenario
    • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Bayer AG
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. AbbVie Inc.
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. Novartis AG
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Oxurion NV.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. Sirnaomics, Inc.
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Alimera Sciences
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. Ampio Pharmaceuticals Inc.
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. BCN Peptides
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. Kowa Company, Ltd.
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Genentech, Inc.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives

관련자료